Liquidia (NASDAQ:LQDA) Now Covered by Oppenheimer

Investment analysts at Oppenheimer began coverage on shares of Liquidia (NASDAQ:LQDA) in a report issued on Tuesday, Briefing.com reports. The brokerage set a “market perform” rating on the stock.

LQDA has been the topic of a number of other reports. Needham & Company LLC restated a “buy” rating and issued a $28.00 price objective on shares of Liquidia in a research note on Monday, June 3rd. HC Wainwright restated a “buy” rating and issued a $32.00 price objective on shares of Liquidia in a research note on Wednesday, May 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $21.00.

Liquidia Stock Up 3.3 %

Shares of LQDA stock opened at $12.60 on Tuesday. Liquidia has a 52 week low of $5.71 and a 52 week high of $16.99. The stock has a market capitalization of $962.39 million, a PE ratio of -8.08 and a beta of 0.25. The firm has a 50 day moving average of $12.95 and a two-hundred day moving average of $13.14.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.22). Liquidia had a negative return on equity of 177.83% and a negative net margin of 674.42%. The firm had revenue of $2.97 million for the quarter, compared to analysts’ expectations of $4.31 million. Analysts expect that Liquidia will post -1.2 EPS for the current fiscal year.

Insider Transactions at Liquidia

In other news, CFO Michael Kaseta sold 3,136 shares of the business’s stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $14.58, for a total transaction of $45,722.88. Following the transaction, the chief financial officer now directly owns 315,045 shares in the company, valued at $4,593,356.10. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Liquidia news, General Counsel Russell Schundler sold 2,060 shares of the company’s stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $14.58, for a total transaction of $30,034.80. Following the transaction, the general counsel now directly owns 486,027 shares in the company, valued at $7,086,273.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Michael Kaseta sold 3,136 shares of the company’s stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $14.58, for a total transaction of $45,722.88. Following the completion of the sale, the chief financial officer now directly owns 315,045 shares in the company, valued at approximately $4,593,356.10. The disclosure for this sale can be found here. Insiders have sold a total of 18,653 shares of company stock worth $270,409 over the last ninety days. 31.60% of the stock is currently owned by company insiders.

Institutional Trading of Liquidia

Several institutional investors and hedge funds have recently modified their holdings of the business. American International Group Inc. lifted its stake in shares of Liquidia by 5.2% during the first quarter. American International Group Inc. now owns 24,806 shares of the company’s stock valued at $366,000 after buying an additional 1,215 shares during the period. Bleakley Financial Group LLC lifted its stake in shares of Liquidia by 6.6% during the first quarter. Bleakley Financial Group LLC now owns 33,250 shares of the company’s stock valued at $490,000 after buying an additional 2,057 shares during the period. Fortitude Family Office LLC purchased a new position in shares of Liquidia during the fourth quarter valued at approximately $26,000. SG Americas Securities LLC increased its position in Liquidia by 17.4% during the fourth quarter. SG Americas Securities LLC now owns 15,540 shares of the company’s stock worth $187,000 after purchasing an additional 2,298 shares during the last quarter. Finally, Corton Capital Inc. increased its position in Liquidia by 14.2% during the third quarter. Corton Capital Inc. now owns 23,440 shares of the company’s stock worth $149,000 after purchasing an additional 2,921 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).